European regulators greenlight U.S. biotech's kidney cancer drug

(Reuters) - European regulators on Friday recommended approving Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a victory for the U.S. biotech that has faced setbacks in bringing the drug to market.